Medical Oncologist
When treatment stops working
Can You Continue the Same Drug — After Progression?
When a scan shows your cancer has grown despite treatment, it is one of the hardest moments in a cancer journey. Understanding why it happened and what comes next can make the next conversation with your oncologist less frightening.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance is biological — Cancer cells evolve under treatment pressure. A drug that worked can stop working when the tumour finds a way around it.
- Progression is not failure — It is a signal to reassess, not a reason to give up. Most patients have options after a first-line treatment stops working.
- Re-testing can guide what comes next — A biopsy or liquid biopsy at progression can identify the resistance mechanism and point to specific next-line agents.
- Clinical trials open here — Progression after first-line treatment is one of the most common eligibility points for trials of newer treatments.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
In most situations, no. When cancer progresses on a drug, it has developed resistance — it has found a way around that treatment. Continuing the same drug rarely helps and delays moving to something that might. Your oncologist will assess what changed and which second-line option fits your situation.
Why does a drug that worked stop working?
Cancer cells divide constantly and accumulate genetic changes. Under pressure from treatment, cells that carry a change giving them an advantage — surviving despite the drug — multiply while others die. Over time, those resistant cells dominate. This is what resistance means in practice.
It does not mean the treatment was wrong, or that you did anything to cause it. It means the cancer adapted, which is a biological property of cancer under selective pressure, not a reflection of how carefully the regimen was followed.
Resistance can develop through several routes — a new mutation in the target gene itself, activation of a parallel signalling pathway the drug does not touch, or changes in how the cell handles the drug. Which route matters because it can help your oncologist choose what to try next.
What does progression mean for your next treatment choice?
Progression on imaging means the cancer has grown or spread while you were on treatment. The first question after that scan is not which drug to switch to — it is understanding why the cancer progressed, and whether re-testing the tumour can guide that choice.
A repeat biopsy or liquid biopsy, where it is safely possible, can identify the resistance mechanism. NCCN and ESMO guidance increasingly recommends molecular re-profiling at progression, particularly for cancers driven by specific mutations.
Not every situation makes re-biopsy practical. Your oncologist will judge whether the result is likely to change the plan, and that depends on what treatment options exist for your cancer type and what re-testing could realistically show.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What will your team check before choosing the next treatment?
- Re-staging scans to map how much the disease has grown and whether new sites have appeared
- Your current performance status — how well you are functioning affects which treatments can safely be offered
- Whether a repeat biopsy or liquid biopsy might reveal the resistance mechanism and guide the next drug choice
- Clinical trial eligibility — progression on first-line treatment is a common entry point for trials of newer agents
- Your own priorities: what you want the next treatment to achieve, and which trade-offs feel acceptable to you
Is there ever a reason to stay on the same treatment after progression?
Occasionally. If progression is limited to one or two sites while the rest of the disease appears controlled — a pattern sometimes called oligoprogression — some oncologists will treat those specific sites with local therapy such as radiation and continue the systemic drug. This is used selectively, not routinely.
ESMO and NCCN acknowledge this approach for specific situations, particularly in certain lung and kidney cancers, though the evidence is still developing. It is not a standard recommendation across cancer types.
A similar consideration sometimes applies to immunotherapy. Because immune responses can lag behind what a scan shows, brief continuation while the pattern is confirmed on a subsequent scan is sometimes appropriate. Your oncologist will know whether this applies to your situation.
What are the main options when a drug stops working?
A different targeted therapy
If your cancer is driven by a specific mutation, there may be a second or third-generation agent designed to work even against the resistant form. For some cancers — EGFR-mutant lung cancer is one example — a sequence of targeted drugs is established in guidelines, and certain agents are designed specifically for the most common resistance mutations. Your oncologist needs to know the resistance mechanism, ideally from re-testing, to match you with the right agent rather than choosing by trial and error.
Chemotherapy as a next line
Chemotherapy works through different mechanisms than targeted therapy and is not subject to the same resistance pathways — which is why it often remains active after a targeted drug has stopped working. The specific regimen depends on your cancer type, what you have already received, and your current fitness. Chemotherapy after a targeted agent is not a step backwards. For many cancers it is the established and clinically effective second-line choice recommended in guidelines from NCCN, ASCO and ESMO.
Immunotherapy, if not already used
If you have not yet received a checkpoint inhibitor and your tumour carries markers that suggest a response, immunotherapy may become an option at this point. Biomarker testing — PD-L1 expression, microsatellite instability, tumour mutational burden — guides that decision. Your oncologist will confirm whether the relevant tests have already been done on your tumour tissue, and whether your cancer type and stage make immunotherapy an established option or something still considered experimental in your setting.
A clinical trial
Progression after a standard first-line treatment is one of the most common eligibility points for clinical trials. Trials of next-generation agents, novel drug combinations, or entirely new drug classes are often designed specifically for patients who have progressed on standard treatment. Your oncologist can check what is currently open in India for your cancer type and prior treatment history. CION participates in selected trials, and eligibility criteria vary — asking the question at your next appointment costs nothing and may open an option you did not know existed.
Focusing on quality of life as a deliberate choice
When further active treatment is unlikely to extend life meaningfully, or would carry more burden than benefit, choosing to focus on symptom control and quality of life is a legitimate medical decision — not a failure, and not giving up. This is best supportive care, and it includes active management of pain, breathlessness, nausea and other symptoms. Asking your oncologist what any proposed next treatment is expected to achieve in your specific situation is a reasonable and important question at every progression, whatever the answer turns out to be.
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does progression mean there are no more treatment options?
No. Progression means the current treatment is no longer controlling the cancer, not that the cancer cannot be treated. For most cancer types, second-line and sometimes third-line options exist in guidelines, and clinical trials expand what is available beyond standard treatment. What changes at each progression is the landscape of options, not whether options exist. Your oncologist can tell you specifically what current evidence supports for your cancer type and what you have already received.
How quickly do we need to decide on a next-line treatment?
In most situations there is time to think — usually enough to complete re-staging, consider re-biopsy, and have a proper conversation. There is rarely a reason to decide within a day or two. If your symptoms are worsening quickly, your oncologist may advise starting sooner, and that advice is worth taking seriously. If you feel rushed without a clear clinical reason, it is reasonable to ask how much time you have and what the consequence of a short delay would be.
Should we get a second opinion after a progression scan?
Yes, and this is one of the most appropriate moments to do so. Progression raises new questions — whether the resistance mechanism has been identified, whether a trial is an option, and whether the proposed next-line treatment matches current guidelines for your specific cancer. Most oncologists expect patients to seek second opinions at progression and will provide the records and imaging needed. Seeking a second opinion does not mean you are leaving your treating team.
Can we go back to a treatment that worked earlier?
Sometimes, though not usually as the immediate next step. Re-challenge — using an earlier drug again after stopping — is used selectively in some cancers, and the evidence for it varies considerably by cancer type. In some situations, a tumour that progressed on one drug and then responded to something different may become sensitive to the first drug again. Whether this applies to your situation is worth asking directly. Your oncologist can tell you what the evidence shows for your specific cancer.
What is a liquid biopsy and can it replace a repeat tumour biopsy?
A liquid biopsy analyses DNA shed by tumour cells into the blood. It is less invasive than a tissue biopsy and can sometimes detect resistance mutations without another tissue procedure. It does not always replace tissue biopsy — the sensitivity varies by cancer type and by how much tumour DNA is circulating — but in many situations it provides useful information more quickly and with less discomfort. Your oncologist will advise which approach makes sense for your cancer and the specific question being asked.
What should we ask at the appointment after a progression scan?
Ask four things: whether re-testing the tumour is recommended and what it might show; what the proposed next-line treatment is and what it is expected to achieve; whether a clinical trial is open for your situation; and what happens if you choose not to start another active treatment, so you understand that option clearly too. Write the answers down or ask for a follow-up call — these decisions are difficult to remember accurately when you are in a distressing appointment.